Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Recruiting

Phase 1

TriCAR19.20.22 T CellsAnti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT07166419

Conditions

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Recurrent Acute Lymphoblastic Leukemia

Recurrent Chronic Lymphocytic Leukemia

Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive

Recurrent Indolent Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autologous Anti-CD19/CD20/CD22 CAR T-cells

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-25. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2025-11-26.